☆ 4.6 Article

Prolonged higher dose methylprednisolone versus conventional dexamethasone in COVID-19 pneumonia: a randomised controlled trial (MEDEAS)

EUROPEAN RESPIRATORY JOURNAL (2023)

相关参考文献

注意：仅列出部分参考文献，下载原文获取全部文献信息。

Article Medicine, General & Internal

Post-COVID-19 syndrome, low-grade inflammation and inflammatory markers: a cross-sectional study

Meryam Maamar et al.

Summary: This study aims to investigate whether subjects with post-COVID syndrome (PCS) after mild COVID-19 have higher levels of inflammatory markers. The results demonstrate a consistent association between PCS and upper ranges of neutrophil count, NLR, fibrinogen, and CRP in the LGI range. Furthermore, the study identifies relevant sex differences in symptoms and markers regarding PCS.

CURRENT MEDICAL RESEARCH AND OPINION (2022)

添加到收藏夹

Article Respiratory System

Effect of high versus low dose of dexamethasone on clinical worsening in patients hospitalised with moderate or severe COVID-19 pneumonia: an open-label, randomised clinical trial

Manuel Taboada et al.

Summary: High-dose dexamethasone reduces clinical worsening in COVID-19 patients receiving oxygen therapy within 11 days after randomization.

EUROPEAN RESPIRATORY JOURNAL (2022)

添加到收藏夹

Article Medicine, General & Internal

Comparison between methylprednisolone infusion and dexamethasone in COVID-19 ARDS mechanically ventilated patients

Mohammed Abdel Monem Saeed et al.

Summary: This study compared the therapeutic effects of methylprednisolone and dexamethasone in patients with severe COVID-19 pneumonia and found that the methylprednisolone group showed significant improvements in clinical outcomes and laboratory results, including reduced mechanical ventilation days, shortened length of stay, and decreased levels of inflammatory markers.

EGYPTIAN JOURNAL OF INTERNAL MEDICINE (2022)

添加到收藏夹

Article Respiratory System

Intravenous methylprednisolone pulses in hospitalised patients with severe COVID-19 pneumonia: a double-blind, randomised, placebo-controlled trial

Carlo Salvarani et al.

Summary: This study evaluated the efficacy and safety of pulse intravenous methylprednisolone in COVID-19 pneumonia patients, and found no significant benefit compared to standard treatment. There were no significant differences in hospital discharge time, survival rates, or overall mortality between the two groups, indicating limited effectiveness of pulse methylprednisolone therapy in treating COVID-19 pneumonia.

EUROPEAN RESPIRATORY JOURNAL (2022)

添加到收藏夹

Article Medicine, General & Internal

Cytokine Profiles as Potential Prognostic and Therapeutic Markers in SARS-CoV-2-Induced ARDS

Francesco Salton et al.

Summary: This study investigated the cytokine profiles in patients with SARS-CoV-2-induced ARDS who were treated with glucocorticoids (GCs). The study found that patients in the invasive mechanical ventilation (IMV) group had higher inflammation levels at intubation compared to the non-invasive ventilation (NIV) group, suggesting a higher resistance to GCs. Further studies are needed to determine the prognostic value of cytokine patterns and the optimal treatment for these patients.

JOURNAL OF CLINICAL MEDICINE (2022)

添加到收藏夹

Article Medicine, General & Internal

COVID-19-Associated Hospitalizations Among Vaccinated and Unvaccinated Adults 18 Years or Older in 13 US States, January 2021 to April 2022

Fiona P. Havers et al.

Summary: Understanding the factors that contribute to hospitalization in vaccinated individuals is crucial for combating COVID-19. This study found that unvaccinated adults were more likely to be hospitalized compared to vaccinated adults, with the lowest hospitalization rates observed in those who had received a booster dose.

JAMA INTERNAL MEDICINE (2022)

添加到收藏夹

Article Medicine, General & Internal

Effect of 12 mg vs 6 mg of Dexamethasone on the Number of Days Alive Without Life Support in Adults With COVID-19 and Severe Hypoxemia The COVID STEROID 2 Randomized Trial

Marie W. Munch et al.

Summary: In patients with COVID-19 and severe hypoxemia, the use of 12 mg/d of dexamethasone compared to 6 mg/d did not lead to a statistically significant difference in the number of days alive without life support at 28 days. The study may have lacked the power to detect a significant effect.

JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2021)

添加到收藏夹

Article Biochemical Research Methods

COVID-19: disease pathways and gene expression changes predict methylprednisolone can improve outcome in severe cases

Sorin Draghici et al.

Summary: The study analyzed different clinical phases of COVID-19 and identified methylprednisolone as a potentially effective therapy for severe symptoms related to hyper-inflammation. Clinical results confirmed that methylprednisolone significantly reduced mortality in COVID-19 patients.

BIOINFORMATICS (2021)

添加到收藏夹

Article Respiratory System

Management of hospitalised adults with coronavirus disease 2019 (COVID-19): a European Respiratory Society living guideline

James D. Chalmers et al.

Summary: This guideline provides clear recommendations for the management of COVID-19 patients, including strong recommendations in favor of systemic corticosteroids and anticoagulation therapy, and conditional recommendations for IL-6 receptor antagonist monoclonal antibody treatment and high-flow nasal oxygen or continuous positive airway pressure in specific situations.

EUROPEAN RESPIRATORY JOURNAL (2021)

添加到收藏夹

Article Infectious Diseases

Methylprednisolone or dexamethasone, which one is superior corticosteroid in the treatment of hospitalized COVID-19 patients: a triple-blinded randomized controlled trial

Keivan Ranjbar et al.

Summary: The study demonstrated that methylprednisolone was more effective than dexamethasone in hospitalized hypoxic COVID-19 patients, with better clinical status, shorter hospital stay, and lower need for a ventilator in the intervention group.

BMC INFECTIOUS DISEASES (2021)

添加到收藏夹

Article Respiratory System

'Long-COVID': a cross-sectional study of persisting symptoms, biomarker and imaging abnormalities following hospitalisation for COVID-19

Swapna Mandal et al.

Summary: Following discharge from hospital, a significant number of COVID-19 patients continue to experience persistent symptoms such as breathlessness, cough, fatigue, and depression. Some patients also show elevated levels of biomarkers indicating ongoing health issues. Chest radiographs reveal abnormalities in a considerable portion of patients, with a small percentage showing deterioration.

THORAX (2021)

添加到收藏夹

Article Critical Care Medicine

Dexamethasone treatment for the acute respiratory distress syndrome: a multicentre, randomised controlled trial

Jesus Villar et al.

LANCET RESPIRATORY MEDICINE (2020)

添加到收藏夹

Review Endocrinology & Metabolism

General Adaptation in Critical Illness: Glucocorticoid Receptor-alpha Master Regulator of Homeostatic Corrections

Gianfranco Umberto Meduri et al.

FRONTIERS IN ENDOCRINOLOGY (2020)

添加到收藏夹

Article Infectious Diseases

A minimal common outcome measure set for COVID-19 clinical research

J. C. Marshall et al.

LANCET INFECTIOUS DISEASES (2020)

添加到收藏夹

Article Medicine, General & Internal

Association Between Administration of Systemic Corticosteroids and Mortality Among Critically Ill Patients With COVID-19 A Meta-analysis

Jonathan A. C. Sterne et al.

JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2020)

添加到收藏夹

Editorial Material Medicine, General & Internal

A living WHO guideline on drugs for covid-19

Francois Lamontagne et al.

BMJ-BRITISH MEDICAL JOURNAL (2020)

添加到收藏夹

Article Immunology

Prolonged Low-Dose Methylprednisolone in Patients With Severe COVID-19 Pneumonia

Francesco Salton et al.

OPEN FORUM INFECTIOUS DISEASES (2020)

添加到收藏夹

Review Critical Care Medicine

Pharmacological principles guiding prolonged glucocorticoid treatment in ARDS

Gianfranco Umberto Meduri et al.

INTENSIVE CARE MEDICINE (2020)

添加到收藏夹

Article Critical Care Medicine

Guidelines for the Diagnosis and Management of Critical Illness-Related Corticosteroid Insufficiency (CIRCI) in Critically Ill Patients (Part I): Society of Critical Care Medicine (SCCM) and European Society of Intensive Care Medicine (ESICM) 2017

Djillali Annane et al.

CRITICAL CARE MEDICINE (2017)

添加到收藏夹

Review Infectious Diseases

Long-term prognosis in community-acquired pneumonia

Marcos I. Restrepo et al.

CURRENT OPINION IN INFECTIOUS DISEASES (2013)

添加到收藏夹

Article Critical Care Medicine

Inflammatory markers at hospital discharge predict subsequent mortality after pneumonia and sepsis

Sachin Yende et al.

AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE (2008)

添加到收藏夹

Article Critical Care Medicine

Hydrocortisone infusion for severe community-acquired pneumonia - A preliminary randomized study

M Confalonieri et al.

AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE (2005)

添加到收藏夹

© Peeref 2019-2024. All rights reserved.